HB 417 (Public Health - Medetomidine and Xylazine Consumer Protection Act) regulates the sale of veterinary drugs medetomidine and xylazine. It prohibits retailers from selling these products without proof the buyer intends to use them for veterinary, scientific, or institutional purposes, and bans sales to anyone under 21. Retailers must maintain records of sales, including age verification and proof of intended use. Violations carry civil fines up to $6,500 per offense, with penalties deposited into Maryland's Substance Abuse Fund. The bill directly affects pharmacies, veterinary suppliers, and online retailers selling these specific products.
HB 202 establishes Maryland's Social Isolation and Loneliness Pilot Grant Program within the Department of Health to fund community programs addressing social isolation. The program awards up to $20,000 per grant to eligible organizations serving vulnerable populations - including youth, seniors, and rural communities - to cover operating costs like staffing and venue fees for socioemotional support services. It requires a $100,000 FY2028 budget appropriation and mandates a program evaluation by December 2029, reporting on financial use and outcomes. The pilot runs from October 2026 through March 2030, focusing on reducing health impacts of isolation without funding research or capital projects.
HB 515 requires that hospital representatives on Maryland's county drug overdose fatality review teams hold specific leadership roles - such as vice president, chief medical officer, or assistant medical officer - instead of any hospital staff member. This change directly affects county-level review teams that analyze overdose deaths, as well as the hospitals participating in them. The bill amends existing law to specify these qualifications for hospital representatives within the team membership structure. It does not create new teams or funding but sets a clearer standard for who can serve in this role. The law takes effect October 1, 2026.
SB 394 adds bacterial vaginosis to Maryland's list of conditions eligible for expedited partner therapy (EPT). This allows certain healthcare providers - like physicians, advanced practice nurses, and pharmaciststo prescribe antibiotics to a sexual partner of a diagnosed patient without requiring a personal examination of the partner. The law aims to prevent reinfection in the diagnosed patient and stop disease spread, expanding existing EPT rules that previously covered only chlamydia, gonorrhea, and trichomoniasis. It applies to public and private health care settings in Maryland starting October 1, 2026.
SB 385 (The Vax Act) requires Maryland’s Secretary of Health to issue evidence-based recommendations for immunizations, screenings, and preventive services, aligning with guidance from major medical organizations like the CDC and U.S. Preventive Services Task Force. It expands pharmacists’ authority to administer vaccines (including those recommended by CDC or the Secretary) to patients aged 3+ after completing specific training and certification, while mandating health insurers to cover these services without cost-sharing. The bill also repeals outdated pertussis-related provisions and updates reporting requirements for pharmacists. This directly affects pharmacists, health insurers, and patients seeking preventive care, aiming to improve access to vaccinations and screenings.
SB 78, the "Protect Our Prostate Act," requires healthcare providers and clinical laboratories to provide standardized information to patients receiving prostate-specific antigen (PSA) tests. It mandates that providers give written preparation instructions before testing, while labs must use FDA-approved tests, calibrate using WHO standards, report results in nanograms per milliliter with reference ranges, and disclose test details to ordering doctors. The law directly affects patients undergoing PSA testing, healthcare providers ordering tests, and clinical laboratories administering the tests. It aims to improve transparency and accuracy of PSA results to help patients understand potential risks like false positives, without changing treatment protocols.
HB 637 ("The Vax Act") requires Maryland's Secretary of Health to issue science-based recommendations for immunizations, screenings, and preventive services using guidance from major medical organizations like the CDC and American Academy of Pediatrics. It expands pharmacists' authority to administer flu, COVID-19, and emergency vaccines to patients aged 3 and older (previously limited to 18+ for some vaccines) after completing specific training. The bill also mandates that health insurance plans cover these recommended services without cost-sharing for patients. This directly affects pharmacists, health insurers, and Maryland residents seeking preventive care, particularly children and adults needing routine vaccinations.
HB 178 establishes three specialized sickle cell disease clinics in Montgomery County, Harford County, and an Eastern Shore county, operating under a hub-and-spoke model to provide comprehensive care including pain management, mental health services, genetic counseling, and social support. It allocates $6.1 million for fiscal year 2028 to fund clinic operations, staff, training, and community partnerships, with priority for addressing social barriers like transportation and housing. The bill also creates a scholarship program for medical residents specializing in sickle cell disease hematology, requiring recipients to practice in Maryland after training. These provisions directly affect Maryland residents living with sickle cell disease, particularly in underserved communities, by expanding access to coordinated care and increasing specialist availability.
HB 446 establishes the Dementia Services and Brain Health Program within Maryland’s Department of Health to lead state public health efforts on brain health and dementia. The program replaces the previous "Director" role for key duties, including staffing the Virginia I. Jones Alzheimer’s Disease and Related Dementias Council and overseeing implementation of the State Plan on Alzheimer’s and related dementias. It requires the program, in partnership with the Department of Aging and other entities, to develop a clinical toolkit for healthcare providers to improve dementia care. The bill updates existing law to formalize this program structure and its responsibilities.
HB 422 expands Maryland's expedited partner therapy (EPT) program to include bacterial vaginosis (BV), allowing certain healthcare providers to prescribe antibiotics to a partner of a diagnosed patient without requiring a physical exam of the partner. The bill specifically adds BV to the list of conditions (alongside chlamydia, gonorrhea, and trichomoniasis) where physicians, nurse practitioners, physician assistants, and designated health department nurses can provide treatment to partners. This applies to patients diagnosed with BV, aiming to reduce reinfection and slow disease spread without requiring partners to visit a clinic. The law takes effect October 1, 2026.
